Abstract
The current study presents the synthesis and characterization of magnetic silica nanocomposites (MSNCs) decorated with Pluronic F127. The nanocomposites were loaded with doxorubicin (DOX) for hepatocellular carcinoma (HCC) therapy. The X-ray diffraction (XRD) patterns proved that the nanocomposites were crystalline with diffraction peaks at 2θ = 35.44° corresponding to (311) plane of Fe3O4. The in vitro test demonstrated cell viability of above 90% revealing that MSNCs-F127 were biocompatible and nontoxic to the HEK293T and HepG2 cell lines; however, the MSNCs-F127-DOX formulations exhibited a significant therapeutic effect against HepG2 cells. A pH-responsive drug release was detected, showing a Higuchi kinetic model at acidic and physiological conditions which demonstrated the best correlation coefficient with R2 values of 0.969, and 0.932, respectively. The highest level of cell inhibitory rate, necrosis, and apoptosis in mice treated with MSNCs-F127-DOX was achieved by in vivo experiment, hematoxylin and eosin (H&E), and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. The in vivo experiment revealed a significant tumor inhibition after treatment with MSNCs-F127-DOX. The prepared MSNCs-F127-DOX formulations could be utilized as an innovative drug delivery system (DDS) for anticancer therapy for several cancer types.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call